Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study

Park, Jin Joo; Lee, Sang-Eun; Cho, Hyun‐Jai; Choi, Jin‐Oh; Yoo, Byung Su; Kang, Seok Min; Wang, Hsiang-Chi; Lee, Sue; Choi, Dong‐Ju

doi:10.36628/ijhf.2022.0015

Cited by 12 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An additional real-world study conducted in Korea demonstrated similar results, including cardiac reverse remodeling, left ventricular size reduction, and LFEF improvement following the initiation of Sac/Val therapy. [25] In the current study, there was a modest increase in BNP levels over the course of 6 months of treatment, rising from 459 (IQR 139-600) pg/mL to 501 (IQR 120-633) pg/mL. Importantly, it should be noted that the baseline BNP levels in our cohort were higher than those reported in the PARADIGM-HF trial.…”

Section: Discussioncontrasting

confidence: 57%

Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia

Badreldin,

Korayem,

Alenazy

et al. 2023

Medicine

View full text Add to dashboard Cite

Despite the demonstrated advantages of angiotensin receptor/neprilysin inhibitors in the management of heart failure, the pivotal Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) trial, which explored this class of medications, did not include individuals from Saudi Arabia. Recognizing that different nations and ethnic groups may exhibit unique characteristics, this study aimed to compare the demographics and outcomes of patients in Saudi Arabia who received sacubitril/valsartan (Sac/Val) with those enrolled in the PARADIGM-HF trial. In this retrospective, multicenter cohort study, we included all adult patients diagnosed with heart failure with reduced ejection fraction (HFrEF) within a tertiary healthcare system in Saudi Arabia between January 2018 and December 2021 and were initiated on Sac/Val. The primary objective was to compare the patient characteristics of those initiating Sac/Val treatment with the participants in the PARADIGM-HF trial. The secondary endpoints included the initiation setting, dose initiation, and titration, as well as alterations in B-type natriuretic peptide and ejection fraction at the 6-month mark. Furthermore, we reported the hospitalization and mortality event rates at the 12-month time point. The study included 400 patients with HFrEF receiving Sac/Val. Compared with the PARADIGM-HF trial, the cohort had a younger mean age and a higher prevalence of diabetes mellitus. SAC/VAL was prescribed as the initial therapy for 34% of the patients, while the remaining participants were initially treated with either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker before transitioning to Sac/Val. Approximately 75% of patients were initiated on 100 mg Sac/Val twice daily, and 90% initiated therapy in the inpatient setting. The mean ejection fraction significantly improved from 26.5 ± 8.4% to 30.5 ± 6.4% at 6 months (P < .001), while the median B-type natriuretic peptide level change was not significant (P = .39). Our study revealed notable disparities in the baseline characteristics of patients with HFrEF compared with those in the PARADIGM-HF trial. These findings offer valuable real-world insights into the prescription patterns and outcomes of Sac/Val in patients with HFrEF in Saudi Arabia, an aspect not previously represented in the PARADIGM-HF study.

show abstract

Section: Discussioncontrasting

confidence: 57%

Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia

Badreldin,

Korayem,

Alenazy

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…ARNI also reduces CV death or HF hospitalizations in hospitalized patients due to acute decompensated HF or in ACEI naïve (i.e., de novo) patients with HFrEF [ 52 , 53 ]. Recent evidence suggests that ARNI could reduce the reliance on diuretics in HFrEF patients [ 54 ] and promotes reverse cardiac remodeling and improves outcomes in patients with HFrEF [ 55 ]. Based on these results, guidelines recommend the use of ARNI in symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death.…”

Section: Treatment Algorithm For Hf In Patients With Dm Focusing On G...mentioning

confidence: 99%

Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

et al. 2023

Self Cite

View full text Add to dashboard Cite

Diabetes mellitus is a major risk factor for the development of heart failure. Furthermore, the prognosis of heart failure is worse in patients with diabetes mellitus than in those without it. Therefore, early diagnosis and proper management of heart failure in patients with diabetes mellitus are important. This review discusses the current criteria for diagnosis and screening tools for heart failure and the currently recommended pharmacological therapies for heart failure. We also highlight the effects of anti-diabetic medications on heart failure.

show abstract

“… 52 53) Recent evidence suggests that ARNI could reduce the reliance on diuretics in HFrEF patients 54) and promotes reverse cardiac remodeling and improves outcomes in patients with HFrEF. 55) Based on these results, guidelines recommend the use of ARNI in symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death. ARNI is also recommended as a replacement for ACEIs or ARBs in patients with HFrEF to reduce the risk of hospitalization for HF and death (if patients tolerate an ACEI or ARB).…”

Section: Treatment Algorithm For Hf In Patients With Dm Focusing On G...mentioning

confidence: 99%

Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study

Cited by 12 publications

References 26 publications

Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia

Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia

Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

Contact Info

Product

Resources

About